UNITED LAB (03933.HK): UBT48128 Obesity Drug Cleared for China Trials
NewTimeSpace News: On 19 November 2026, The United Laboratories International Holdings Limited (stock code: 03933.HK) announced on a voluntary basis that the clinical trial application for UBT48128 Tablets, a Class 1 new drug self-developed by its wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd., for the indication of overweight or obesity has been cleared by China's National Medical Products Administration, with reference numbers CXHL2601252, CXHL2601253 and CXHL2601254.
UBT48128 Tablets are a small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist that works through multiple mechanisms, including promoting insulin secretion, controlling appetite and modulating energy metabolism. Once-daily oral administration lowers blood glucose and reduces body weight, potentially improving patient adherence. Preclinical studies in multiple animal models showed that UBT48128 significantly reduces body weight, with weight-loss effects superior to those of the control groups, and the Company expects the product to demonstrate promising therapeutic potential as a new option for patients who are overweight or obese.
According to the announcement, UBT48128 Tablets were approved by the US Food and Drug Administration for an Investigational New Drug application on 11 August 2026. The Company said it will continue to advance new product research and development, strengthen its competitiveness and innovation in the biopharmaceutical industry and focus on chronic disease treatment, which is expected to generate greater value for the Company and its shareholders.
- UNITED LAB (03933.HK): Semaglutide Weight Management Application Accepted
- UNITED LAB (03933.HK): semaglutide weight-management filing accepted
- United Lab(3933.HK) gets US$9M second milestone from Novo for UBT251
- UNITED LAB (03933.HK): NMPA Accepts Filing for IDegLira; First Chinese Biosimilar Applicant
- UNITED LAB (03933.HK): UBT251 injection completes first participant dosing in Phase III clinical study for type 2 diabetes in China